PharmiWeb.com - Global Pharma News & Resources
15-Sep-2020

AI & Medicine Provides Insights on What AI Is

AI & Medicine recently published an article on its website, explaining what artificial intelligence (AI) is for people who are keen on AI technology. The company has been expanding application of its AI-Powered Drug Discovery platform to personalized healthcare and various other medical applications, as revealed by its spokesperson in previous months.

The emergence of AI has played a key part in ushering in a new ear and it is disrupting almost every industry in every country, especially in life sciences. As its name suggests, an AI is a computer system that is able to perform tasks that ordinarily require human intelligence. In general, these most talked about artificial intelligence systems relies on four major technologies: machine learning, deep learning, natural language processing, and robotics and the internet of things.

Drug R&D is publicly viewed as a very complicated, costly and time-consuming attempt. The use of AI and machine learning in the early stages of drug discovery and development will save lots of time, money and effort, and thus being extensively explored. Through big data analysis and other technical means, AI-powered drug discovery platform can quickly and accurately mine data and select the appropriate lead compounds.

AI & Medicine’s expertise lies in the following scenarios:

Drug Target Discovery

Candidate Drug Discovery

Prediction of Drug Crystal Form

ADMET Prediction

Design and Optimization of Clinical Trials

Patient Screening and Recruitment

Pharmacovigilance

Meanwhile, in the article, AI & Medicine’s experts also indicates that the key trends and considerations in pharma's operating approach include:

  • Partnerships with AI companies would be a new trend that benefit from each other.
  • Forming partnerships to share data between pharma companies, helps to optimize the potential benefits of AI.
  • Algorithm transparency with regulators would help regulators to better understand the processes behind AI-powered conclusions.
  • Companies must take appropriate legal and compliance measures to protect patient’s data privacy.
  • Intellectual property protection should be strengthened, including foreground and background IP, the ownership of trained model/derived data, the exploitation rights, etc.

For medical institutions and pharmaceutical enterprises that are interested to learn more information about AI & Medicine’s capability in drug research and development solutions, please visit: https://aimed.protheragen.com/.

About AI & Medicine

Missioned to helping fulfill the specific drug R&D requirements in the industry, AI & Medicine successfully develops an AI-powered drug discovery platform for medical institutions and pharmaceutical enterprises across the globe, offering a broad and integrated portfolio of medical and scientific solutions in areas like drug R&D, medical translation, medical imaging, medical therapy and research system, and more. It recently broadens its service offerings to chemical drug development, molecular docking, de novo drug design, retrosynthetic analysis, docking and scoring, SAR analysis, etc.

Editor Details

Last Updated: 18-Sep-2020